Does the media prefer EVH or SDGR?

In the previous week, Evolent Health had 9 more articles in the media than Schrodinger. MarketBeat recorded 14 mentions for Evolent Health and 5 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.94 beat Evolent Health's score of -0.24 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GDRX or EVH?

GoodRx has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.60 $30.44M $0.04 93.00 Evolent Health $1.88B 0.27 -$534.51M -$4.57 N/A

Is GDRX or EVH more profitable?

GoodRx has a net margin of 2.07% compared to Evolent Health's net margin of -24.08%. GoodRx's return on equity of 7.22% beat Evolent Health's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.07% 7.22% 2.53% Evolent Health -24.08% -4.27% -1.06%

Does the media favor GDRX or EVH?

In the previous week, Evolent Health had 1 more articles in the media than GoodRx. MarketBeat recorded 14 mentions for Evolent Health and 13 mentions for GoodRx. GoodRx's average media sentiment score of 0.63 beat Evolent Health's score of -0.24 indicating that GoodRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GoodRx 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolent Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to EVH or CERT?

In the previous week, Evolent Health had 10 more articles in the media than Certara. MarketBeat recorded 14 mentions for Evolent Health and 4 mentions for Certara. Certara's average media sentiment score of 1.36 beat Evolent Health's score of -0.24 indicating that Certara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Certara 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EVH or TDOC?

In the previous week, Evolent Health had 5 more articles in the media than Teladoc Health. MarketBeat recorded 14 mentions for Evolent Health and 9 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 0.57 beat Evolent Health's score of -0.24 indicating that Teladoc Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Teladoc Health 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EVH or HSTM?

In the previous week, Evolent Health had 10 more articles in the media than HealthStream. MarketBeat recorded 14 mentions for Evolent Health and 4 mentions for HealthStream. HealthStream's average media sentiment score of 1.43 beat Evolent Health's score of -0.24 indicating that HealthStream is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral HealthStream 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evolent Health (EVH) Competitors

$4.45 -0.23 (-4.91%)

Closing price 08/17/2026 03:58 PM Eastern

Extended Trading

$4.46 +0.01 (+0.22%)

As of 06:00 AM Eastern

Compare

EVH vs. SDGR, GDRX, CERT, TDOC, and HSTM

Should you buy Evolent Health stock or one of its competitors? Evolent Health's main competitors and comparable companies include Schrodinger (SDGR), GoodRx (GDRX), Certara (CERT), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Evolent Health compare to Schrodinger?

Evolent Health (NYSE:EVH) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

79.1% of Schrodinger shares are held by institutional investors. 1.5% of Evolent Health shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evolent Health presently has a consensus price target of $6.04, suggesting a potential upside of 35.63%. Schrodinger has a consensus price target of $20.50, suggesting a potential upside of 17.82%. Given Evolent Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Evolent Health is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Evolent Health has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Schrodinger has a net margin of -20.98% compared to Evolent Health's net margin of -24.08%. Evolent Health's return on equity of -4.27% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
Schrodinger	-20.98%	-16.37%	-8.19%

In the previous week, Evolent Health had 9 more articles in the media than Schrodinger. MarketBeat recorded 14 mentions for Evolent Health and 5 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.94 beat Evolent Health's score of -0.24 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Schrodinger has lower revenue, but higher earnings than Evolent Health. Schrodinger is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.27	-$534.51M	-$4.57	N/A
Schrodinger	$259.04M	4.96	-$103.26M	-$0.74	N/A

Summary

Evolent Health and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

How does Evolent Health compare to GoodRx?

GoodRx (NASDAQ:GDRX) and Evolent Health (NYSE:EVH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

GoodRx has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.60	$30.44M	$0.04	93.00
Evolent Health	$1.88B	0.27	-$534.51M	-$4.57	N/A

GoodRx presently has a consensus target price of $4.14, indicating a potential upside of 11.19%. Evolent Health has a consensus target price of $6.04, indicating a potential upside of 35.63%. Given Evolent Health's stronger consensus rating and higher possible upside, analysts clearly believe Evolent Health is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

63.8% of GoodRx shares are owned by institutional investors. 5.9% of GoodRx shares are owned by insiders. Comparatively, 1.5% of Evolent Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GoodRx has a net margin of 2.07% compared to Evolent Health's net margin of -24.08%. GoodRx's return on equity of 7.22% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
Evolent Health	-24.08%	-4.27%	-1.06%

GoodRx has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Evolent Health has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

In the previous week, Evolent Health had 1 more articles in the media than GoodRx. MarketBeat recorded 14 mentions for Evolent Health and 13 mentions for GoodRx. GoodRx's average media sentiment score of 0.63 beat Evolent Health's score of -0.24 indicating that GoodRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolent Health	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

GoodRx beats Evolent Health on 11 of the 16 factors compared between the two stocks.

How does Evolent Health compare to Certara?

Evolent Health (NYSE:EVH) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Certara has a net margin of -16.75% compared to Evolent Health's net margin of -24.08%. Certara's return on equity of 3.86% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
Certara	-16.75%	3.86%	2.65%

In the previous week, Evolent Health had 10 more articles in the media than Certara. MarketBeat recorded 14 mentions for Evolent Health and 4 mentions for Certara. Certara's average media sentiment score of 1.36 beat Evolent Health's score of -0.24 indicating that Certara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Certara	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Certara has lower revenue, but higher earnings than Evolent Health. Certara is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.27	-$534.51M	-$4.57	N/A
Certara	$418.84M	2.91	-$1.60M	-$0.45	N/A

Evolent Health currently has a consensus target price of $6.04, suggesting a potential upside of 35.63%. Certara has a consensus target price of $8.28, suggesting a potential upside of 3.47%. Given Evolent Health's stronger consensus rating and higher probable upside, research analysts clearly believe Evolent Health is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Evolent Health has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Certara has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

74.0% of Certara shares are held by institutional investors. 1.5% of Evolent Health shares are held by insiders. Comparatively, 1.1% of Certara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Certara beats Evolent Health on 10 of the 17 factors compared between the two stocks.

How does Evolent Health compare to Teladoc Health?

Evolent Health (NYSE:EVH) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Evolent Health presently has a consensus price target of $6.04, indicating a potential upside of 35.63%. Teladoc Health has a consensus price target of $7.54, indicating a potential upside of 15.22%. Given Evolent Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Evolent Health is more favorable than Teladoc Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Evolent Health has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

76.8% of Teladoc Health shares are held by institutional investors. 1.5% of Evolent Health shares are held by insiders. Comparatively, 0.7% of Teladoc Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Teladoc Health has a net margin of -7.13% compared to Evolent Health's net margin of -24.08%. Evolent Health's return on equity of -4.27% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
Teladoc Health	-7.13%	-12.15%	-5.83%

In the previous week, Evolent Health had 5 more articles in the media than Teladoc Health. MarketBeat recorded 14 mentions for Evolent Health and 9 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 0.57 beat Evolent Health's score of -0.24 indicating that Teladoc Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Teladoc Health	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teladoc Health has higher revenue and earnings than Evolent Health. Teladoc Health is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.27	-$534.51M	-$4.57	N/A
Teladoc Health	$2.49B	0.48	-$200.32M	-$0.99	N/A

Summary

Evolent Health and Teladoc Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Evolent Health compare to HealthStream?

Evolent Health (NYSE:EVH) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, Evolent Health had 10 more articles in the media than HealthStream. MarketBeat recorded 14 mentions for Evolent Health and 4 mentions for HealthStream. HealthStream's average media sentiment score of 1.43 beat Evolent Health's score of -0.24 indicating that HealthStream is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
HealthStream	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HealthStream has a net margin of 6.60% compared to Evolent Health's net margin of -24.08%. HealthStream's return on equity of 6.81% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
HealthStream	6.60%	6.81%	4.64%

Evolent Health currently has a consensus price target of $6.04, indicating a potential upside of 35.63%. HealthStream has a consensus price target of $27.00, indicating a potential downside of 3.64%. Given Evolent Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evolent Health is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.6% of HealthStream shares are owned by institutional investors. 1.5% of Evolent Health shares are owned by insiders. Comparatively, 20.4% of HealthStream shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evolent Health has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

HealthStream has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.27	-$534.51M	-$4.57	N/A
HealthStream	$304.06M	2.69	$18.34M	$0.72	38.92

Summary

HealthStream beats Evolent Health on 10 of the 16 factors compared between the two stocks.

Get Evolent Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVH vs. The Competition

Export

Metric	Evolent Health	Healthcare Technology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$529.12M	$1.62B	$7.03B	$24.35B
Dividend Yield	N/A	4.70%	2.56%	3.69%
P/E Ratio	-0.97	21.37	270.81	30.51
Price / Sales	0.27	75.85	560.83	20.20
Price / Cash	1.00	30.69	28.87	20.48
Price / Book	1.26	5.62	11.16	4.92
Net Income	-$534.51M	-$26.60M	$3.45B	$1.07B
7 Day Performance	8.94%	0.90%	0.62%	0.13%
1 Month Performance	-23.47%	6.20%	2.09%	2.60%
1 Year Performance	-50.99%	-17.89%	61.61%	18.42%

Evolent Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVH Evolent Health	2.3406 of 5 stars	$4.45 -4.9%	$6.04 +35.6%	-52.2%	$529.12M	$1.88B	N/A	4,200	Analyst Forecast Gap Up
SDGR Schrodinger	1.8708 of 5 stars	$18.16 +2.0%	$20.25 +11.5%	-10.2%	$1.31B	$255.87M	N/A	790
GDRX GoodRx	3.7931 of 5 stars	$3.68 -1.1%	$4.15 +12.7%	-0.3%	$1.27B	$796.85M	92.02	950	Analyst Upgrade
CERT Certara	2.0159 of 5 stars	$8.20 +0.9%	$8.28 +0.9%	-27.4%	$1.24B	$418.84M	N/A	1,576
TDOC Teladoc Health	3.2279 of 5 stars	$7.12 +6.5%	$7.54 +5.9%	-12.9%	$1.21B	$2.53B	N/A	5,600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVH) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolent Health (EVH) Competitors

EVH vs. SDGR, GDRX, CERT, TDOC, and HSTM

How does Evolent Health compare to Schrodinger?

Summary

How does Evolent Health compare to GoodRx?

Summary

How does Evolent Health compare to Certara?

Summary

How does Evolent Health compare to Teladoc Health?

Summary

How does Evolent Health compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVH vs. The Competition

Evolent Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolent Health (EVH) Competitors

EVH vs. SDGR, GDRX, CERT, TDOC, and HSTM

How does Evolent Health compare to Schrodinger?

Do insiders & institutionals believe in EVH or SDGR?

Do analysts prefer EVH or SDGR?

Which has more volatility and risk, EVH or SDGR?

Is EVH or SDGR more profitable?

Does the media prefer EVH or SDGR?

Which has preferable earnings & valuation, EVH or SDGR?

Summary

How does Evolent Health compare to GoodRx?

Which has preferable earnings and valuation, GDRX or EVH?

Do analysts recommend GDRX or EVH?

Do insiders & institutionals believe in GDRX or EVH?

Is GDRX or EVH more profitable?

Which has more volatility & risk, GDRX or EVH?

Does the media favor GDRX or EVH?

Summary

How does Evolent Health compare to Certara?

Is EVH or CERT more profitable?

Does the media refer more to EVH or CERT?

Which has preferable earnings & valuation, EVH or CERT?

Do analysts prefer EVH or CERT?

Which has more risk and volatility, EVH or CERT?

Do institutionals and insiders hold more shares of EVH or CERT?

Summary

How does Evolent Health compare to Teladoc Health?

Do analysts recommend EVH or TDOC?

Which has more risk and volatility, EVH or TDOC?

Do insiders & institutionals have more ownership in EVH or TDOC?

Is EVH or TDOC more profitable?

Does the media prefer EVH or TDOC?

Which has higher earnings and valuation, EVH or TDOC?

Summary

How does Evolent Health compare to HealthStream?

Does the media prefer EVH or HSTM?

Is EVH or HSTM more profitable?

Do analysts rate EVH or HSTM?

Do institutionals & insiders believe in EVH or HSTM?

Which has more volatility and risk, EVH or HSTM?

Which has preferable earnings and valuation, EVH or HSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVH vs. The Competition

Evolent Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools